Pfizer registers Phase 3 trial of PF-08653944 in Chinese adults with overweight or obesity
The study plans to enroll an estimated 432 participants and compares berobenatide (PF-08653944) with placebo. It is scheduled to start on October 15, 2026, with primary completion expected on June 6, 2028.
Primary source
ClinicalTrials.gov registry record, October 15, 2026
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Read the source: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation